Monica Robles, MD
Endocrinology, Diabetes & Metabolism · Anniston, ALNPI 1750502183
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by AstraZeneca at 56.6% of the total. Reporting peaked in 2019 at $6,457 and has fallen 80.8% since, to $1,238 in 2025.
Across 560 payments — averaging $31.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Dexcom, Inc.$1K
- Xeris Pharmaceuticals, Inc.$914
- Novo Nordisk$902
- Abbott$878
- Lilly USA, LLC$767
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$9,55054%
- Travel & lodging$810%
- Food & beverage$7,94745%
- Education$1271%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $10,048 |
| Dexcom, Inc. | 100 | $1,231 |
| Xeris Pharmaceuticals, Inc. | 57 | $914 |
| Novo Nordisk | 104 | $902 |
| Abbott | 62 | $878 |
| Lilly USA, LLC | 51 | $767 |
| Medtronic(2 entities) | 32 | $628 |
| Sanofi-aventis U.S. LLC | 20 | $272 |
| Amgen(2 entities) | 18 | $271 |
| Corcept Therapeutics | 10 | $199 |
| Kyowa Kirin, Inc. | 7 | $141 |
| Bayer | 7 | $136 |
| Mannkind Corporation | 5 | $116 |
| Tandem Diabetes Care, Inc. | 7 | $112 |
| AbbVie | 7 | $108 |
| Boehringer Ingelheim | 6 | $98 |
| Insulet Corporation | 5 | $94 |
| Amarin Pharma, Inc. | 6 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $80 |
| IBSA Pharma Inc. | 4 | $76 |
| BETA Bionics, Inc. | 3 | $75 |
| Esperion Therapeutics, Inc. | 2 | $70 |
| Amphastar Pharmaceuticals, Inc. | 3 | $66 |
| BD | 3 | $65 |
| Novartis | 4 | $64 |
| Pfizer | 4 | $61 |
| Zealand Pharma US, Inc. | 3 | $52 |
| Amneal Pharmaceuticals LLC | 2 | $32 |
| Lifescan, Inc. | 2 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Sequel Med Tech, LLC | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$9,675
- MINIMED 780G$146
How this compares
$17,765 in reported general payments places this provider in the 75th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,675 | $2,486,782 |
| MounjaroTirzepatide | 850 | $1,318,522 |
| JardianceEmpagliflozin | 1,041 | $1,168,806 |
| TrulicityDulaglutide | 652 | $952,817 |
| FarxigaDapagliflozin Propanediol | 213 | $248,255 |
| Tresiba Flextouch U-100Insulin Degludec | 243 | $232,811 |
| RybelsusSemaglutide | 114 | $229,546 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 130 | $173,878 |
| JanuviaSitagliptin Phosphate | 171 | $161,303 |
| Tresiba Flextouch U-200Insulin Degludec | 121 | $157,373 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 760 | $133,921 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 124 | $130,099 |
| Humalog Kwikpen U-100Insulin Lispro | 415 | $128,111 |
| Novolog FlexpenInsulin Aspart | 454 | $127,552 |
| Gvoke Hypopen 2-PackGlucagon | 167 | $117,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $902 | $2,851,3181,959 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $767 | $2,311,3981,600 claims |
| Boehringer IngelheimJardiance, Tradjenta | $98 | $1,200,1801,095 claims |
| AstraZenecaFarxiga | $10,048 | $248,255213 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $32 | $27,1412,004 claims |
| AbbVieSynthroid | $108 | $23,168263 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Anniston
- Neil SchaffnerOpelika$642K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
- William GarveyBirmingham$421K
- Judson MenefeeFairhope$168K
- William DebellTuscaloosa$161K
- Edison GoncalvesBirmingham$142K
- David BellIrondale$112K
- Bethany JacksonFlorence$90K
- Dwain WoodeHuntsville$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.